Niagen Bioscience, Inc.
corporate_fare Company Profile
Niagen Bioscience, Inc. (NASDAQ:NAGE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for NAGE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 8/10, with 7 rated 8 or above. Recent SEC coverage for NAGE spans 10-Q, 8-K, S-3, 10-K.
Recent high-impact activity:
- Q3 Sales Fall 20% to $27.2M as Niagen Swings to $1.2M Net Loss
- Niagen Q3 Sales Fall 20% to $27.2M; Swings to $1.2M Loss as Ingredient Demand Slips
- Niagen Q3 Sales Fall 20% to $27.2M; Net Loss of $1.2M as Ingredient Business Slumps
- Niagen Bioscience Q2 Sales Miss, Net Income Plunges 73%
- Niagen Bioscience Q2 Miss: Sales Slip, Profits Collapse, and Legal Clouds Gather
Financial Snapshot
Short Interest & Short Volume
8.91 days to coverFINRA reported short interest of 4,348,687 shares in NAGE as of the October 30, 2026 settlement, a 4.2% increase from the prior period — about 8.9 days to cover at its recent average daily volume. On November 20, 2026, 46.0% of NAGE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for NAGE, detected from its recent SEC filings · based on capital-structure filings through 2026-07-10.
ATM Program Activation · Use of Proceeds
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →